MDL® Isentris® chosen by Ciba Specialty Chemicals as global integration platform for R&D Chemistry Database

State-of-the-art, MDL technology provides Ciba with a solid foundation for their new chemical information system

San Leandro, CA – January 9, 2005 – Elsevier MDL is pleased to announce that Ciba Specialty Chemicals has licensed the MDL® Isentris® information management and integration platform for its global R&D operations. MDL Isentris, is the first out-of-the-box, n-tier discovery informatics platform specifically designed for life sciences and materials researchers.

Martin Weber Nisslé, the Head of R&D Systems, Global Information Services for Ciba Specialty Chemicals stated, “Ciba Specialty Chemicals wants to further strengthen its focus on innovation and fast R&D processes with a new chemical information system that allows global access to a single corporate chemistry database. MDL Isentris will help Ciba implement this deadline-driven project by providing an integration platform for scientific and technical information, both proprietary and from literature.”

“MDL Isentris improves the overall productivity of pharmaceutical and specialty chemical research by enhancing the integration of scientific content and workflow applications,” said Lars Barfod, president and CEO of Elsevier MDL. “State-of-the-art, Isentris technology with its capability of seamlessly migrating chemical information will provide Ciba with a solid foundation for their new chemical information system. We are delighted that Ciba has chosen Isentris.”

The MDL Isentris platform consists of four products: MDL® Base desktop interface for scientists, MDL® Draw chemical drawing software, MDL® Core Interface middle tier for building and integrating Web and desktop applications and MDL® Direct chemical data cartridges for storing, searching and retrieving molecules and reactions in Oracle® databases.

MDL Isentris is the next-generation in cheminformatics technology and the successor to MDL ISIS, which has been the industry-standard for pharmaceutical research for over ten years. Isentris is an open architecture designed to work with in-house applications and third-party tools. Additionally, there is a growing group of companies collaborating via the MDL Isentris Alliance to provide interoperable tools on the Isentris platform.

To learn more about MDL Isentris, contact your Elsevier MDL Account Manager or visit

About Elsevier MDL
Elsevier MDL provides informatics, database and workflow solutions that accelerate successful life sciences R&D by improving the speed and quality of scientists’ decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit Elsevier is a world-leading publisher of scientific, technical and medical information products and services. For more information visit

Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries.

Media Contact:

Dr. Phil McHale  
Elsevier MDL 
VP, Market & Corporate Communications 
Phone: (510) 357-2222 ext. 3541